Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda S Steelman

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
Cell Cycle (Georgetown, Tex.)|October 31, 2009
Intriguing novel abilities of Nutlin-3A: induction of cellular quiescence as opposed to cellular senescence--implications for chemotherapyLinda S Steelman, James A McCubrey
Cell Cycle (Georgetown, Tex.)|November 14, 2002
Raf-induced cell cycle progression in human TF-1 hematopoietic cellsFumin Chang, Linda S Steelman, James A McCubrey
International Journal of Oncology|January 16, 2003
EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review)Patrick M Navolanic, Linda S Steelman, James A McCubrey
Expert Opinion on Therapeutic Targets|December 9, 2004
The complexity of PTEN: mutation, marker and potential target for therapeutic interventionLinda S Steelman, Fred E Bertrand, James A McCubrey
Cancer Research|November 19, 2004
Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cellsJohn T Lee, Linda S Steelman, James A McCubrey
International Journal of Oncology|May 5, 2005
Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cellsJohn T Lee, Linda S Steelman, James A McCubrey
Oncotarget|April 14, 2011
Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicityLinda S Steelman, Alberto M Martelli, Ferdinando Nicoletti, et al.
Cell Cycle (Georgetown, Tex.)|January 17, 2004
Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cellsJohn G Shelton, Linda S Steelman, Edmond R White, et al.
Cancer Biology & Therapy|November 15, 2002
The effects of beta-estradiol on Raf activity, cell cycle progression and growth factor synthesis in the MCF-7 breast cancer cell lineCaroline R Weinstein-Oppenheimer, Carlo Burrows, Linda S Steelman, et al.
Cell Cycle (Georgetown, Tex.)|February 8, 2008
Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cellsJohn T Lee, Linda S Steelman, William H Chappell, et al.
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
Cell Cycle (Georgetown, Tex.)|October 31, 2009
Intriguing novel abilities of Nutlin-3A: induction of cellular quiescence as opposed to cellular senescence--implications for chemotherapyLinda S Steelman, James A McCubrey
Cell Cycle (Georgetown, Tex.)|November 14, 2002
Raf-induced cell cycle progression in human TF-1 hematopoietic cellsFumin Chang, Linda S Steelman, James A McCubrey
International Journal of Oncology|January 16, 2003
EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review)Patrick M Navolanic, Linda S Steelman, James A McCubrey
Expert Opinion on Therapeutic Targets|December 9, 2004
The complexity of PTEN: mutation, marker and potential target for therapeutic interventionLinda S Steelman, Fred E Bertrand, James A McCubrey
Cancer Research|November 19, 2004
Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cellsJohn T Lee, Linda S Steelman, James A McCubrey
International Journal of Oncology|May 5, 2005
Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cellsJohn T Lee, Linda S Steelman, James A McCubrey
Oncotarget|April 14, 2011
Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicityLinda S Steelman, Alberto M Martelli, Ferdinando Nicoletti, et al.
Cell Cycle (Georgetown, Tex.)|January 17, 2004
Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cellsJohn G Shelton, Linda S Steelman, Edmond R White, et al.
Cancer Biology & Therapy|November 15, 2002
The effects of beta-estradiol on Raf activity, cell cycle progression and growth factor synthesis in the MCF-7 breast cancer cell lineCaroline R Weinstein-Oppenheimer, Carlo Burrows, Linda S Steelman, et al.
Cell Cycle (Georgetown, Tex.)|February 8, 2008
Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cellsJohn T Lee, Linda S Steelman, William H Chappell, et al.
Pageof 10